CHMP Archives

Home CHMP

Latest Posts

News and Trends 29 Aug 2022

Marketing authorization granted for treatment of serious retinal diseases

The European Commission has granted marketing authorization to Ranivisio, a treatment for several serious retinal diseases. Polpharma Biologics Group BV, Formycon AG and their Swiss joint venture, Bioeq AG, announced the news today (August 29) that the authorization was granted to Ranivisio, which is a biosimilar to Lucentis, a ranibizumab injection. Positive opinion: CHMP The […]

August 29, 2022 - 3 minutesmins - By Liza Laws

News and Trends 25 Jul 2022

Drug that could be the first and only in Europe to treat rare brain condition recommended for marketing authorization

The Committee for Medical Products for Human Use (CHMP) has recommended the European Commission (EC) make a marketing authorization under exceptional circumstances for a drug to treat a rare condition characterized by brain dysfunction. The drug is called NULIBRY (fosdenopterin) for injection therapy for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A. […]

July 25, 2022 - 4 minutesmins - By Liza Laws

lupus autoimmune disease neutrophil citryll

News and Trends 22 Jul 2022

Positive news for Aurinia’s voclosporin drug Lupkynis to treat lupus nephritis

British Columbia-based Aurinia Pharmaceuticals Inc. announced today (July 22) that its voclosporin drug has been recommended for marketing authorization to treat adults with active lupus nephritis (LN). The Canadian biopharma company said it is committed to delivering therapeutics that change the course of autoimmune disease after the Committee for Medicinal Products for Human Use (CHMP) […]

July 22, 2022 - 3 minutesmins - By Liza Laws

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us